High-yield strain is designed to accelerate production of human growth hormone.
Dowpharma licensed its Pfenex Expression Technology™ to India-based Biovel Life Sciences. The agreement grants Biovel rights to employ the Pseudomonas fluorescense-based technology for the production of human growth hormone (HGH), a biosimilar product.
Dowpharma says it has already developed a high-yield production strain and process for the production of HGH and will prepare and transfer to Biovel a research cell bank and the production process. The agreement provides for an upfront technology access fee, maintenance and milestone fees, as well as royalties on product sales.